Christoph B. Olivier, Annabel Hölzle/LinkedIn
Mar 13, 2026, 22:05
Christoph B. Olivier: Annabel Hölzle Shared Critical Findings on HALT After TAVR
Christoph B. Olivier, Head of the Clinical Trials Unit, UHZ Freiburg, shared on LinkedIn, adding:
”Congratulations Annabel for an outstanding presentation at the Spring School 2026!
Today Annabel Hölzle shared critical findings from her study: ‘Periprocedural hemostatic and inflammatory changes after TAVR and their association with hypoattenuating leaflet thickening (HALT).’
Her research provides vital clues to improve long-term patient safety in heart valve interventions.
We are very proud to see our team members leading such high-impact clinical discussions.
Great job, Annabel!”
Stay updated with Hemostasis Today.
-
Aug 13, 2026, 18:39Lukas Röthlisberger: Real-World Evidence on Effectiveness and Safety of Rivaroxaban in Children
-
Aug 13, 2026, 18:36Soner Yilmaz: Blood Safety in Türkiye Through More Than 22.5 Million Blood Donations
-
Aug 13, 2026, 18:31Muthukumarasamy Raja: FDA Approval of EZPLAZ Marks a Breakthrough in Emergency Plasma Care
-
Aug 13, 2026, 18:29Peter Zdziarski: Protecting Our Community While Creating a Future Where We Are No Longer Needed
-
Aug 13, 2026, 18:29Morgan E Amos: Thrilled to Receive the Student Research Award From HTRS
-
Aug 13, 2026, 16:38Sheharyar Raza: Plasma Exchange in Multiple Sclerosis
-
Aug 13, 2026, 16:31Juan Manuel Cisneros Carrasco: The True Cost of Blood Donation
-
Aug 13, 2026, 16:25Connie Montgomery: Bridging the Gap Between Patients, Culture and Clinical Trials
-
Aug 13, 2026, 16:16Isabella Presch: A New AI Approach to Protein Engineering